Ahmed I Salem1, Mina Alfi2, Emily Winslow1, Clifford S Cho1, Sharon M Weber1. 1. Department of Surgery, University of Wisconsin Hospital and Clinics, Madison, Wisconsin. 2. University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.
Abstract
INTRODUCTION: Survival following resection of pancreas cancer is poor. It is uncertain whether outcome improved overtime. Due to the recent advances in surgical techniques, diagnostic evaluation, and systemic treatment, we sought to evaluate pancreas cancer outcome over time. METHODS: Prospectively collected data on patients who underwent pancreaticoduodenectomy for pathologically confirmed pancreatic adenocarcinoma from 1999 to 2012 were analyzed. Perioperative and long-term outcomes were analyzed, comparing patients from era 1 (1999-2005) to patients from era 2 (2006-2012). RESULTS: Two-hundred sixteen patients were evaluated, including 76 in era 1 and 140 in era 2. There was no difference in 30-day mortality (1.3%, era 1 vs. 1.4%, era 2; P = 0.95) or rates of overall 30-day morbidity (49%, era 1 vs. 62%, era 2; P = 0.06). On multivariable analysis after adjusting for perineural invasion, lymphovascular invasion, margin status, EBL, and venous resection, there was no difference in survival between eras (HR = 0.81, P = 0.27, CI = 0.57-1.16). CONCLUSIONS: After adjusting for clinicopathological features, there was no association of improved outcome over time. However, despite an increasing prevalence of anatomically advanced and histologically aggressive tumors, perioperative outcomes such as blood loss and margin negativity improved over time, with no increase in 30-day mortality.
INTRODUCTION: Survival following resection of pancreas cancer is poor. It is uncertain whether outcome improved overtime. Due to the recent advances in surgical techniques, diagnostic evaluation, and systemic treatment, we sought to evaluate pancreas cancer outcome over time. METHODS: Prospectively collected data on patients who underwent pancreaticoduodenectomy for pathologically confirmed pancreatic adenocarcinoma from 1999 to 2012 were analyzed. Perioperative and long-term outcomes were analyzed, comparing patients from era 1 (1999-2005) to patients from era 2 (2006-2012). RESULTS: Two-hundred sixteen patients were evaluated, including 76 in era 1 and 140 in era 2. There was no difference in 30-day mortality (1.3%, era 1 vs. 1.4%, era 2; P = 0.95) or rates of overall 30-day morbidity (49%, era 1 vs. 62%, era 2; P = 0.06). On multivariable analysis after adjusting for perineural invasion, lymphovascular invasion, margin status, EBL, and venous resection, there was no difference in survival between eras (HR = 0.81, P = 0.27, CI = 0.57-1.16). CONCLUSIONS: After adjusting for clinicopathological features, there was no association of improved outcome over time. However, despite an increasing prevalence of anatomically advanced and histologically aggressive tumors, perioperative outcomes such as blood loss and margin negativity improved over time, with no increase in 30-day mortality.
Authors: Noah S Rozich; Alessandra Landmann; Casey S Butler; Morgan M Bonds; Laura E Fischer; Russell G Postier; Katherine T Morris Journal: J Surg Res Date: 2018-08-31 Impact factor: 2.192
Authors: Jordan M Cloyd; Matthew H G Katz; Laura Prakash; Gauri R Varadhachary; Robert A Wolff; Rachna T Shroff; Milind Javle; David Fogelman; Michael Overman; Christopher H Crane; Eugene J Koay; Prajnan Das; Sunil Krishnan; Bruce D Minsky; Jeffrey H Lee; Manoop S Bhutani; Brian Weston; William Ross; Priya Bhosale; Eric P Tamm; Huamin Wang; Anirban Maitra; Michael P Kim; Thomas A Aloia; Jean-Nicholas Vauthey; Jason B Fleming; James L Abbruzzese; Peter W T Pisters; Douglas B Evans; Jeffrey E Lee Journal: J Gastrointest Surg Date: 2016-10-24 Impact factor: 3.452
Authors: Hazem Zakaria; Ahmed N Sallam; Islam I Ayoub; Emad H Gad; Mohammad Taha; Michael R Roshdy; Dina Sweed; Nahla K Gaballa; Taha Yassein Journal: Ann Med Surg (Lond) Date: 2020-08-11
Authors: Cole R Drifka; Agnes G Loeffler; Kara Mathewson; Adib Keikhosravi; Jens C Eickhoff; Yuming Liu; Sharon M Weber; W John Kao; Kevin W Eliceiri Journal: Oncotarget Date: 2016-11-15
Authors: Hyun Ju Kim; Woo Jung Lee; Chang Moo Kang; Ho Kyoung Hwang; Seung Min Bang; Si Young Song; Jinsil Seong Journal: PLoS One Date: 2016-06-22 Impact factor: 3.240